1211877-22-3

Basic information

• Product Name: ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester
• Synonyms: ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester
• CAS NO: 1211877-22-3
• Molecular Weight: 477.645
• Mol File: 1211877-22-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester(1211877-22-3)
• EPA Substance Registry System: ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester(1211877-22-3)

Safety Data

• Hazardous Substances Data: 1211877-22-3(Hazardous Substances Data)

Upstream product

• 1211877-18-7 C₂₈H₄₅N₃O₆ 
• 7533-40-6 (S)-2-amino-4-methylpentan-1-ol 
• 7801-71-0 N-benzyloxycarbonyl-L-leucyl-L-leucine 
• 2018-66-8 Z-Leu-OH 
• 3504-37-8 Cbz-L-Leu-L-Leu-OMe 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 82010-31-9 (S)-(1-hydroxymethyl-3-methylbutyl)carbamic acid tert-butyl ester 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 61-90-5 L-leucine 
• 1334176-68-9 Boc-L-leucine-L-leucinol 
• 1334176-70-3 C₂HF₃O₂*C₁₂H₂₆N₂O₂ 

Downstream Products

• 133407-82-6 N-(benzyloxycarbonyl)-leucinylleucinylleucinal 
• 1374568-54-3 benzyl (S)-1-{(S)-1-[(S)-1,1-diiodo-5-methyl-2-oxohexan-3-yl-amino]-4-methyl-1-oxopentan-2-ylamino}-4-methyl-1-oxopentan-2-ylcarbamate 

Relevant articles and documents

Application of proteasome inhibitor in inhibition of novel coronavirus

The invention provides application of a proteasome inhibitor in inhibition of a novel coronavirus or preparation of novel coronavirus inhibitors. The proteasome inhibitor has a structure represented by a formula (I) or isomers, pharmaceutically acceptable salts thereof and prodrugs thereof. According to the application, by applying the proteasome inhibitor to inhibition of the novel coronavirus, good inhibiting activity is obtained, and a novel treatment way of think is provided for diseases such as pneumonia caused by the novel coronavirus.

Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif

The ubiquitin-proteasome system (UPS) has been successfully targeted by both academia and the pharmaceutical industry for oncological and immunological applications. Typical proteasome inhibitors are based on a peptidic backbone endowed with an electrophi

Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach

MG-132 is a tripeptide aldehyde (Z-L-leu-L-leu-L-leu-H, 2) proteasome inhibitor that exerts antitumor activity and enhances cytostatic/cytotoxic effects of chemo- and radiotherapy. Because of a troublesome synthesis of tripeptides with a non-natural configuration and modified side chains of amino acids, only two stereoisomers of MG-132 have been reported. Here, we propose a new approach to the synthesis of tripeptide aldehydes based on the Ugi reaction. Chiral, enantiomerically stable 2-isocyano-4-methylpentyl acetates were used as substrates for Ugi reaction resulting in a formation of tripeptide skeletons. Further functionalization of the obtained products led to a synthesis of tripeptide aldehydes. All stereoisomers of MG-132 were synthesized and studied as potential inhibitors of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities of proteasome. These studies demonstrated the influence of absolute configuration of chiral aldehydes on the cytostatic/cytotoxic effects of the synthesized compounds and revealed that only (S,R,S)-(-)-2 stereoisomer is a more potent. proteasome inhibitor than MG-132.